KCT0007811招募中未知
Effects of herbal medicine (Eulja-tang) for grade ? to ? hemorrhoids with chronic constipation: a randomized, open-label, active-comparator controlled, parallel, exploratory clinical trial
Daejeon Korean Medicine Hospital of Daejeon University0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1) Men and women between the ages of 19 and 65
- •2) Patients diagnosed with functional constipation according to Rome IV diagnostic criteria
- •3) Patients with grade 1 or grade 2 according to Goliger classification
- •4) Those who voluntarily agreed in writing to participate in this clinical trial
排除标准
- •1) Those with a history of using constipation treatment drugs (bulking laxatives, stool softeners, dietary fiber products, etc.), constipation-inducing drugs, enemas and suppositories, and hemorrhoids ointment within the last 2 weeks
- •2) Those who have received oriental medical treatment such as acupuncture, moxibustion, cupping, or herbal medicine for the purpose of treating constipation or hemorrhoids within the last 2 weeks
- •3) Those with a Sodergren score of 6 or higher or those with a grade 3 or higher according to Goligher's classification which are eligible for surgery
- •4) Metabolic disease (hypothyroidism, diabetes, hypercalcemia, etc.), myopathy (amyloidosis), nervous system disease (Parkinson's disease, multiple sclerosis, spinal cord injury, etc.), constipation or drug-induced constipation due to underlying diseases such as depression is suspected one who becomes
- •5) In case of acute abdominal disease (appendicitis, intestinal bleeding, ulcerative colitis, etc.), intestinal obstruction, intestinal stenosis, or severe gastrointestinal symptoms, or an anal disease accompanied by dentition, fistula, perianal abscess, anal pruritus, anal Crohn's disease, etc.
- •6) Those who have been diagnosed with inflammatory bowel disease or an organic disease (colon cancer, etc.) within 6 months or have the following warning symptoms or signs within 3 months: Bloody stools accompanied by anemia not considered to be the cause of hemorrhoids or hemorrhoids, recently those who have lost 5% or more of their total body weight in 3 months, constipation within 3 months
- •7) Those with a history of abdominal surgery (except for appendectomy, hernia surgery, cholecystectomy, cesarean section)
- •8) Those who have had hemorrhoid surgery within 12 months prior to screening
- •9) Clinically significant diseases and disorders in the liver, kidney, cardiovascular system, respiratory system, endocrine system, and central nervous system in physical examination and clinical examination, or cerebrovascular disease (cerebral infarction, cerebral hemorrhage) within 6 months before screening; Those with a history of heart disease (angina pectoris, myocardial infarction, heart failure, etc.), severe nervous system disease, kidney disease, immunodeficiency disease, active hepatitis B or C, active tuberculosis, asthma, COPD, malignancy or mental illness
- •10) Patients with hepatic and renal dysfunction (at screening, ALT, AST, r-GTP = 3 times the upper limit of normal, blood creatinine = 2 times the upper limit of normal)
- •11) Uncontrolled diabetic patients (glycated hemoglobin level 9% or higher or fasting blood sugar 160mg/dL or higher at screening)
- •12) With abnormal Free T4 on the thyroid function test, TSH < 0.1 uIU/ml or TSH > 5.1 uIU/ml at screening
- •13) Those who have a history of hypersensitivity to the components of the drug for clinical trials
- •14) Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •15) A person with a history of alcoholic or drug abuse
- •16) Pregnant, lactating, or planning to become pregnant within 3 months
- •17) Those who participated in other clinical trials taking clinical investigational drugs within 30 days before participation in this clinical trial (based on the date of written consent)
- •18) In case the investigator judges that it is not suitable for the clinical trial for other reasons
研究者
相似试验
招募中
3 期
Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patientsIRCT20200404046935N1Mazandaran University of Medical Sciences40
尚未招募
3 期
The effect of herbal medicine (Tiryaqe wabai) on anxiety, depression and sleep in the elderlyCondition 1: Depression. Condition 2: anxiety disorder.Persistent mood [affective] disordersGeneralized anxiety disorderF41.1IRCT20211017052785N2Karaj University of Medical Sciences108
已完成
3 期
Efficacy of herbal drug in the treatment of children with intractable epilepsyEpilepsy.IRCT2015091515790N2Vice-Chancellor for research affairs of Mashhad University of Medical Sciences44
已完成
2 期
Evaluation of the effects of herbal medicine (Mixture) ?on Polycystic ovary syndrome (PCOS) in women and girls with PCOS sign and symptomPolycystic ovarian syndromePolycystic ovary syndrome.IRCT201609015942N4Vice chancellor for Research,Tabriz University Of Medical Sciences60
招募中
3 期
The effect of Wound Healer on diabetic footDiabetic patient with infected foot ulcer.Type 2 diabetes mellitus with other specified complicationsE11.6IRCT20111228008551N3Tehran University of Medical Sciences80